$8356 | SAVE $1,139 | Single User
$16711 | SAVE $2,279 | Site License
$25067 | SAVE $3,418 | Enterprise License

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024
[Published by Global Data]

Published by Global Data: 01 Jan 2016 | 18125 | In Stock
Related Topics: Biosimilars , Humira , Roche

Introduction

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Summary

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.

Highlights

Key Questions Answered

- How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?

- What opportunities remain in the market for new product entrants?

- With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?

- According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?

- What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?

Key Findings

- Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.

- Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.

- Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.

- With several major pharmaceutical companies involved in development of vasculitis products, the market will be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.

Scope

- Overview of vasculitis, including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.

- Annualized vasculitis market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the vasculitis market.

- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically BMS’s Orencia, GSK’s Benlysta and Nucala, Genentech/Roche’s Actemra, Celgene’s Otezla, J&J’s Remicade, and biosimilars (such as Celltrion/Hospira/Alvogen’s Inflectra/Remsima).

- Analysis of the current and future market competition in the global vasculitis market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the vasculitis market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vasculitis market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global vasculitis market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 10

    1.1 List of Tables 15

    1.2 List of Figures 19

    2 Introduction 20

    2.1 Catalyst 20

    2.2 Related Reports 21

    2.3 Upcoming Related Reports 21

    3 Disease Overview 22

    3.1 Types of Vasculitis 22

    3.2 Etiology and Pathophysiology 23

    3.2.1 Large Vessel Vasculitis 23

    3.2.2 Kawasaki Disease 24

    3.2.3 ANCA-Associated Small Vessel Vasculitis 25

    3.2.4 Behҫet’s Disease 26

    3.3 Symptoms 26

    3.4 Disease Management 27

    3.4.1 Classification Criteria 27

    3.4.2 Disease Management Guidelines 28

    4 Epidemiology 34

    4.1 Disease Background 34

    4.2 Risk Factors and Comorbidities 35

    4.3 Global Trends 36

    4.4 Forecast Methodology 39

    4.4.1 Sources Used 41

    4.4.2 Sources Not Used 61

    4.4.3 Forecast Assumptions and Methods 61

    4.5 Epidemiological Forecast for Vasculitis, 2014-2024 85

    4.5.1 Diagnosed Incident Cases of AAV 85

    4.5.2 Diagnosed Prevalent Cases of AAV 87

    4.5.3 Age-Standardized Incidence of AAV 89

    4.5.4 Diagnosed Incident Cases of LVV - TA and GCA 92

    4.5.5 Diagnosed Prevalent Cases of TA 94

    4.5.6 Age-Standardized Incidence of LVV 96

    4.5.7 Diagnosed Incident Cases of BD 98

    4.5.8 Diagnosed Prevalent Cases of BD 100

    4.5.9 Age-Standardized Incidence of BD 102

    4.5.10 Diagnosed Incident Cases of KD 103

    4.6 Discussion 105

    4.6.1 Epidemiological Forecast Insight 105

    4.6.2 Limitations of the Analysis 106

    4.6.3 Strengths of the Analysis 107

    5 Current Treatment Options 109

    5.1 Overview 109

    5.2 Product Profiles 111

    5.2.1 Rituxan (Rituximab) 111

    5.2.2 Humira (Adalimumab) 115

    5.2.3 Remicade (Infliximab) 120

    5.2.4 Mycophenolate Mofetil 125

    5.2.5 Cyclophosphamide 129

    5.2.6 Azathioprine 133

    5.2.7 Methotrexate 137

    5.2.8 Glucocorticoids 140

    5.2.9 Intravenous Immunoglobulin 143

    6 Unmet Needs Assessment and Opportunity Analysis 147

    6.1 Overview 147

    6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting 148

    6.2.1 Unmet Need 148

    6.2.2 Gap Analysis 149

    6.2.3 Opportunity 151

    6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting 151

    6.3.1 Unmet Need 151

    6.3.2 Gap Analysis 152

    6.3.3 Opportunity 153

    6.4 Biomarkers to Predict Responsiveness to Therapy 154

    6.4.1 Unmet Need 154

    6.4.2 Gap Analysis 154

    6.4.3 Opportunity 154

    6.5 Biomarkers to Predict Disease Relapse 155

    6.5.1 Unmet Need 155

    6.5.2 Gap Analysis 155

    6.5.3 Opportunity 156

    6.6 Early and Non-invasive Diagnosis of Vasculitis 156

    6.6.1 Unmet Need 156

    6.6.2 Gap Analysis 157

    6.6.3 Opportunity 158

    6.7 Adjunctive Therapy for the Treatment of KD 158

    6.7.1 Unmet Need 158

    6.7.2 Gap Analysis 160

    6.7.3 Opportunity 161

    7 R&D Strategies 163

    7.1 Overview 163

    7.2 Expansion for Key Autoimmune Drugs 163

    7.3 Shift Towards Vasculitis as a Primary Indication 164

    7.4 Clinical Trial Design 165

    7.4.1 Current Clinical Trial Design 166

    7.4.2 Challenges in Vasculitis Clinical Trial Design 169

    8 Pipeline Assessment 171

    8.1 Overview 171

    8.2 Promising Drugs in Clinical Development 171

    8.2.1 Orencia (Abatacept) 172

    8.2.2 Benlysta (Belimumab) 176

    8.2.3 Actemra (Tocilizumab) 180

    8.2.4 Otezla (Apremilast) 184

    8.2.5 Nucala (Mepolizumab) 188

    8.3 Additional Drugs in Development for Vasculitis 192

    9 Pipeline Valuation Analysis 195

    9.1 Clinical Benchmark of Key Pipeline Drugs 195

    9.1.1 AAV 195

    9.1.2 LVV 196

    9.1.3 KD 196

    9.1.4 BD 197

    9.2 Commercial Benchmark of Key Pipeline Drugs 198

    9.2.1 AAV 198

    9.2.2 LVV 199

    9.2.3 KD 199

    9.2.4 BD 200

    9.3 Competitive Assessment 202

    9.3.1 AAV 202

    9.3.2 LVV 203

    9.3.3 KD 204

    9.3.4 BD 204

    9.4 Top Line Ten Year Forecast 205

    9.4.1 US 210

    9.4.2 5EU 212

    9.4.3 Japan 213

    10 Appendix 215

    10.1 Bibliography 215

    10.2 Abbreviations 234

    10.3 Methodology 240

    10.4 Forecasting Methodology 240

    10.4.1 Percent Drug-treated Patients 240

    10.4.2 Drugs Included in Each Therapeutic Class 240

    10.4.3 Launch and Patent Expiry Dates 241

    10.4.4 General Pricing Assumptions 242

    10.4.5 Individual Drug Assumptions 243

    10.4.6 Generic Erosion 251

    10.4.7 Pricing of Pipeline Agents 251

    10.5 Primary Research 252

    10.5.1 Physicians and Specialists Included in this Study 252

    10.5.2 Online Survey of High Prescribing Physicians 253

    10.6 About the Authors 254

    10.6.1 Author 254

    10.6.2 Reviewer 254

    10.6.3 Epidemiologist 255

    10.6.4 Global Director of Therapy Analysis and Epidemiology 255

    10.6.5 Global Head of Healthcare 256

    10.7 About GlobalData 257

    10.8 Disclaimer 257

List Of Tables
in OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Symptoms of Selected Types of Vasculitis 27

Table 2: Nine Recommendations for the Management of BD 30

Table 3: Clinical and Laboratory Features of KD 31

Table 4: Risk Factors and Comorbidities for Vasculitis 36

Table 5: 2012 Revised CHCC Definitions of Vasculitides 40

Table 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of MPA 41

Table 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MPA 42

Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GPA 43

Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of GPA 44

Table 10: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of eGPA 45

Table 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of eGPA 46

Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of GCA 47

Table 13: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of TA 48

Table 14: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of TA 49

Table 15: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of BD 50

Table 16: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of BD 51

Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of KD 52

Table 18: 7MM, Sources Not Used in Epidemiological Analysis of AAV, LVV, BD, and KD 61

Table 19: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 86

Table 20: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 88

Table 21: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024 93

Table 22: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024 95

Table 23: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 99

Table 24: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 101

Table 25: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024 104

Table 26: Leading Treatments for Vasculitis, 2015 109

Table 27: Current Treatment Options for Vasculitis Across the 7MM, November 2015 111

Table 28: Product Profile - Rituxan 113

Table 29: Rituxan SWOT Analysis, 2015 115

Table 30: Product Profile - Humira 117

Table 31: Humira SWOT Analysis, 2015 120

Table 32: Product Profile - Remicade 122

Table 33: Completed trials demonstrating Remicade as a potential treatment for vasculitis 123

Table 34: Remicade SWOT Analysis, 2015 125

Table 35: Product Profile - Mycophenolate Mofetil 126

Table 36: Evidence for Mycophenolate Mofetil Treatment Therapy in Vasculitis 127

Table 37: MMF SWOT Analysis, 2015 129

Table 38: Product Profile - CYC 130

Table 39: Evidence for cyclophosphamide treatment therapy in vasculitis 131

Table 40: CYC SWOT Analysis, 2014 132

Table 41: Product Profile - Azathioprine 134

Table 42: Evidence for azathioprine treatment therapy in vasculitis 135

Table 43: Azathioprine SWOT Analysis, 2015 137

Table 44: Product Profile - Methotrexate 138

Table 45: Evidence for Methotrexate treatment therapy in vasculitis 139

Table 46: Methotrexate SWOT Analysis, 2015 140

Table 47: Product Profile - Glucocorticoids 141

Table 48: Evidence for Glucocorticoid Treatment Therapy in Vasculitis 142

Table 49: GC SWOT Analysis, 2015 143

Table 50: Product Profile - Intravenous Immunoglobulin 144

Table 51: Evidence for Intravenous Immunoglobulin Therapy in Vasculitis 145

Table 52: GC SWOT Analysis, 2015 146

Table 53: Unmet Need and Opportunity in Vasculitis, 2015 148

Table 54: Vasculitis - Late Stage Pipeline, December 2015 172

Table 55: Product Profile - Orencia 174

Table 56: Orencia SWOT Analysis, 2015 176

Table 57: Product Profile - Benlysta 178

Table 58: Benlysta SWOT Analysis, 2015 179

Table 59: Product Profile - Actemra 181

Table 60: Clinical Trials Demonstrating Actemra as a Potential Treatment for Vasculitis 182

Table 61: Actemra SWOT Analysis, 2015 184

Table 62: Product Profile - Otezla 186

Table 63: Otezla SWOT Analysis, 2015 188

Table 64: Product Profile - Nucala 190

Table 65: Completed Trials Demonstrating Nucala as a Potential Treatment for eGPA 191

Table 66: Nucala SWOT Analysis, 2015 192

Table 67: Early-Stage Pipeline Products in Vasculitis, November 2015 194

Table 68: Clinical Benchmark of Key Pipeline Drugs for AAV 196

Table 69: Clinical Benchmark of Key Pipeline Drugs for LVV, KD, and BD 197

Table 70: Commercial Benchmark of Key Pipeline Drugs for AAV 199

Table 71: Commercial Benchmark of Key Pipeline Drugs for LVV, KD, and BD 201

Table 72: Top-Line Sales Forecasts ($m) for Vasculitis, 2014-2024 206

Table 73: Key Events Impacting Sales for Vasculitis, 2014-2024 209

Table 74: Global Vasculitis Disease Market - Drivers and Barriers, 2014-2024 210

Table 75: Key Launch Dates 241

Table 76: Key Patent Expiries 241

Table 77: Average Body Weight and Surface Area Across the 7MM 243

Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 253

List Of Figures, Charts and Diagrams
in OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Classification of Systemic Vasculitides as Defined by CHCC 2012 23

Figure 2: 7MM, Diagnosed Incident Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 87

Figure 3: 7MM, Diagnosed Prevalent Cases of AAV, Ages ≥15 Years, Both Sexes, N, 2014-2024 89

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MPA, Ages ≥15 Years, Both Sexes, N, 2014 90

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of GPA, Ages ≥15 Years, Both Sexes, N, 2014 91

Figure 6: 7MM, Age-Standardized Incidence of eGPA, Ages ≥15 Years, Both Sexes, N, 2014 92

Figure 7: 7MM, Diagnosed Incident Cases of LVV, Ages ≥15 Years, Both Sexes, N, 2014-2024 94

Figure 8: 7MM, Diagnosed Prevalent Cases of TA, Ages ≥15 Years, Both Sexes, N, 2014-2024 96

Figure 9: 7MM, Age-Standardized Diagnosed Incidence of GCA, Ages ≥15 Years, Both Sexes, N, 2014 97

Figure 10: 7MM, Age-Standardized Diagnosed Incidence of TA, Ages ≥15 Years, Both Sexes, N, 2014 98

Figure 11: 7MM, Diagnosed Incident Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 100

Figure 12: 7MM, Diagnosed Prevalent Cases of BD, Ages ≥15 Years, Both Sexes, N, 2014-2024 102

Figure 13: 7MM, Age-Standardized Incidence of BD, Ages ≥15 Years, Both Sexes, N, 2014 103

Figure 14: 7MM, Diagnosed Incident Cases of KD, Ages ≤5 Years, Both Sexes, N, 2014-2024 105

Figure 15: Competitive Assessment of AAV Pipeline Therapies, 2014-2024 202

Figure 16: Competitive Assessment of LVV, KD, and BD Pipeline Therapies, 2014-2024 203

Figure 17: Global Sales for Vasculitis by Region, 2014-2024 207

Figure 18: Global Sales for Vasculitis by Indication, 2014-2024 208

Additional Details

Publisher

Global Data

Publisher Information

Reference

18125 | GDHC045POA

Number of Pages

258

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024SummaryHuntingt...
03 May 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 20...
02 Feb 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 202...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024S...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024Summa...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024Summ...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024SummaryHodg...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024SummaryGlioblastoma mu...
22 Dec 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to ...
09 Oct 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024Summary...
08 Sep 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info

This report is published by Global Data

Download Free Report Summary PDF

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...